Drug Trial Radar · NCT07465276
Neoadjuvant Ficerafusp Alfa With Pembrolizumab in Resectable SCC
Last checked: Nov 19, 2026Latest source record: Mar 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
32
Planned (sponsor's estimate)
Start
Mar 26, 2026
Primary completion
Apr 30, 2028
Study completion Apr 30, 2030
Sponsor
- Lead sponsor
- Dana-Farber Cancer InstituteAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Bicara Therapeutics
- First posted
- Mar 11, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This trial is to evaluate the safety and efficacy of ficerafusp alfa in combination with pembrolizumab prior to surgical resection in participants with resectable, high-risk, locoregionally advanced, PD-L1-positive squamous cell carcinoma of the head and neck (HNSCC). The names of the study drugs used in this research study are: * ficerafusp alfa (a type of bifunctional antibody and recombinant fusion protein) * pembrolizumab (a type of monoclonal antibody)
Conditions
- Head and Neck Squamous Cell Carcinoma (HNSCC)
- Squamous Cell Carcinoma of the Head and Neck
Interventions
Ficerafusp alfaDrug
Bifunctional antibody and recombinant fusion protein, single-use vial, via intravenous (into the vein) infusion per protocol.
PembrolizumabDrug
Monoclonal antibody, single-dose vial, via intravenous infusion per protocol.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Pathologic Treatment Response-2 (pTR-2) RateTime frame: Assessed at time of surgical resection, between days 30 and 42 from start of neoadjuvant treatment.
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Brigham and Women's Hospital
Boston, Massachusetts · Recruiting
Dana-Farber Cancer Institute
Boston, Massachusetts · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.